Premium
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)
Author(s) -
Buzdar Aman U.,
Blumenschein George R.,
Smith Terry L.,
Tashima Charles K.,
Hortobagyi Gabriel N.,
Yap H. Yong,
Gutterman Jordan U.,
Hersh Evan M.,
Gehan Edmund A.
Publication year - 1979
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930120105
Subject(s) - medicine , chemoimmunotherapy , cyclophosphamide , breast cancer , adjuvant , surgery , regimen , stage (stratigraphy) , radiation therapy , oncology , chemotherapy , cancer , paleontology , biology
A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.